Grenoble-based Diabeloop snaps up €31 million to expand reach of AI device for type 1 diabetes | EU-Startups

▤ Summary

French company Diabeloop has announced securing a €31 million Series B round of funding, breaking the European record for therapeutic AI fundraising. Even so, the device reduces the burden typically associated with treatments, improving quality of life for patients. Reflecting on the success of the Series B fundraising, Erik Huneker, founder and co-CEO of Diabeloop, explains, “Our technology is unique. The Diabeloop-developed algorithm adapts to the physiology and lifestyle of each person, which means the glucose trend prediction and insulin delivery are customized. Patients have provided extremely positive feedback, especially in terms of quality of life, as the daily burden of multiple therapeutic decisions is alleviated.”

▦ Linked Companies